Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Systemic Juvenile Idiopathic Arthritis (β-SPECIFIC 1)
NCT00886769Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Dec 2010
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in systemic juvenile idiopathic arthritis (SJIA) comparing Canakinumab Arm with Placebo Arm (2 arms). Primary endpoint: Adapted American College of Rheumatology Pediatric 30 Criteria at Day 15. Started Jul 2009; status: terminated.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT00886769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00886769.